BusinessFormation Bio Announces $600 Million Fund for Clinical-Stage Drug ProgramsBy Helena WardOct 28, 2026, 6:29 PM UTC
HealthRoche Signs Conditional Global License Deal for Zymeworks’ ZW209 ProgramBy Naomi CalderOct 23, 2026, 8:34 PM UTC
BusinessOpenAI Acquires Orchestra Bio to Develop AI Tools for Drug ProgramsBy Helena WardOct 21, 2026, 12:45 PM UTC
BusinessFDA & Industry Veteran Brian E. Harvey, MD, PhD, Joins Thetis Pharmaceuticals as Senior Medical DirectorBy Nasdaq OMXMay 7, 2018, 4:27 PM UTC
BusinessCURE Pharmaceutical Attracts Strategic Investment to Speed Its Cannabinoid Drug Delivery ProductionBy Nasdaq OMXMay 1, 2018, 12:57 PM UTC
BusinessCrownBio Launches New Humanized Target Model for ImmunotherapyBy Nasdaq OMXApr 26, 2018, 12:00 PM UTC
BusinessBiopharmaceutical Veteran Joins CURE Pharmaceutical to Lead ManufacturingBy Nasdaq OMXMar 14, 2018, 1:01 PM UTC
BusinessInside Science: Alzheimer's Drug Trials Keep Failing -- It May Be Because We Don't Understand the DiseaseBy Nasdaq OMXMar 13, 2018, 8:29 PM UTC
